| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Innovating Pharma Commercialization And Efficiency To Propel Revenue And Margins
Cencora, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$234.44 |
| 52 Week High | US$247.66 |
| 52 Week Low | US$171.65 |
| Beta | 0.45 |
| 11 Month Change | 3.00% |
| 3 Month Change | 8.43% |
| 1 Year Change | 29.96% |
| 33 Year Change | 96.15% |
| 5 Year Change | 184.96% |
| Change since IPO | 7,838.71% |
Recent News & Updates
Recent updates
Market Participants Recognise Cencora, Inc.'s (NYSE:COR) Earnings
Jul 16
Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning
Jun 30Are Investors Undervaluing Cencora, Inc. (NYSE:COR) By 43%?
Jun 28Here's Why Cencora (NYSE:COR) Can Manage Its Debt Responsibly
Jun 09Do Cencora's (NYSE:COR) Earnings Warrant Your Attention?
May 21Investors Interested In Cencora, Inc.'s (NYSE:COR) Earnings
Apr 05Cencora Remains Chronically Undervalued, With Material Growth Potential
Mar 25Cencora, Inc.'s (NYSE:COR) Intrinsic Value Is Potentially 53% Above Its Share Price
Mar 18Cencora (NYSE:COR) Seems To Use Debt Quite Sensibly
Feb 25Cencora (NYSE:COR) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Feb 07Cencora, Inc.'s (NYSE:COR) Business Is Yet to Catch Up With Its Share Price
Jan 05Cencora: Continued Economic Value On The Table Across All Investment Horizons
Jan 04A Look At The Fair Value Of Cencora, Inc. (NYSE:COR)
Dec 15Cencora (NYSE:COR) Is Paying Out A Larger Dividend Than Last Year
Nov 05Is Cencora (NYSE:COR) A Risky Investment?
Nov 03Cencora: New Name, Same Old Economic Leverage, Reiterate Buy
Oct 18AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 34% Below Their Intrinsic Value Estimate
Aug 01AmerisourceBergen: Great Company, Wrong Price (Rating Downgrade)
Jul 28We Think AmerisourceBergen (NYSE:ABC) Can Stay On Top Of Its Debt
Jun 19Is AmerisourceBergen Corporation (NYSE:ABC) Trading At A 28% Discount?
May 01Here's Why We Think AmerisourceBergen (NYSE:ABC) Is Well Worth Watching
Apr 10AmerisourceBergen (NYSE:ABC) Has A Pretty Healthy Balance Sheet
Mar 02AmerisourceBergen declares $0.485 dividend
Feb 01AmerisourceBergen Corporation (NYSE:ABC) Shares Could Be 25% Below Their Intrinsic Value Estimate
Jan 28AmerisourceBergen partners with pharmaceutical company Civica
Jan 23AmerisourceBergen: What Does The Valuation Look Like After The Recent Price Rise?
Jan 13Does AmerisourceBergen (NYSE:ABC) Deserve A Spot On Your Watchlist?
Jan 10AmerisourceBergen sued by DoJ over suspicious opioid orders
Dec 29Shareholder Returns
| COR | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -1.8% | 1.2% | 0.1% |
| 1Y | 30.0% | 13.9% | 24.9% |
Return vs Industry: COR exceeded the US Healthcare industry which returned 14.1% over the past year.
Return vs Market: COR exceeded the US Market which returned 25.9% over the past year.
Price Volatility
| COR volatility | |
|---|---|
| COR Average Weekly Movement | 2.6% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: COR has not had significant price volatility in the past 3 months.
Volatility Over Time: COR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 44,000 | Steve Collis | www.cencora.com |
Cencora, Inc. sources and distributes pharmaceutical products. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Cencora, Inc. Fundamentals Summary
| COR fundamental statistics | |
|---|---|
| Market cap | US$46.60b |
| Earnings (TTM) | US$1.86b |
| Revenue (TTM) | US$283.83b |
24.8x
P/E Ratio0.2x
P/S RatioIs COR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COR income statement (TTM) | |
|---|---|
| Revenue | US$283.83b |
| Cost of Revenue | US$274.27b |
| Gross Profit | US$9.56b |
| Other Expenses | US$7.71b |
| Earnings | US$1.86b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.47 |
| Gross Margin | 3.37% |
| Net Profit Margin | 0.65% |
| Debt/Equity Ratio | 446.1% |
How did COR perform over the long term?
See historical performance and comparison